Clicky

Dyne Therapeutics, Inc.(DYN)

Description: Dyne Therapeutics is building a leading muscle disease company focused on advancing innovative life-transforming therapeutics for patients with genetically driven diseases. The Company utilizes its proprietary FORCEā„¢ platform to overcome the current limitations of muscle tissue delivery with modern oligonucleotide therapeutic candidates. Dyne is developing a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD).


Keywords: Disease Medical Genetics Dystrophy Muscular Dystrophy Duchenne Muscular Dystrophy Oligonucleotide Duchenne Genetic Genealogy Myotonic Dystrophy Dystrophin Facioscapulohumeral Muscular Dystrophy Muscle Disease Muscle Diseases

Home Page: www.dyne-tx.com

DYN Technical Analysis

1560 Trapelo Road
Waltham, MA 02451
United States
Phone: 781 786 8230


Officers

Name Title
Mr. Joshua T. Brumm CEO, Pres & Director
Ms. Susanna Gatti High M.B.A. Chief Operating Officer
Dr. Oxana Beskrovnaya Ph.D. Chief Scientific Officer
Dr. Romesh Subramanian Ph.D. Co-Founder & Advisor
Mr. Gene Kim VP of Fin.
Mr. Richard William Scalzo M.B.A. Sr. VP, Head of Fin. & Admin. and Treasurer
Ms. Amy Reilly Sr. VP and Head of Corp. Communications & Investor Relations
Ms. Kate Mitchell VP & Head of HR
Dr. Thomas-Christian Mix M.D., M.S. Sr. VP of Pharmacovigilance
Ms. Debra Feldman Sr. VP & Head of Regulatory Affairs

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 2.2375
Price-to-Sales TTM: 0
IPO Date: 2020-09-17
Fiscal Year End: December
Full Time Employees: 115
Back to stocks